H. pylori eradication does not reduce gastric cancer incidence in a high-risk area of China

Research output: Contribution to journalComment/debatepeer-review

1 Citation (Scopus)

Abstract

Question. Does treating H. Pylori reduce the incidence of gastric cancer? Study. Randomised placebo-controlled trial. Main results. At 7.5 years, incidence of gastric cancer was not significantly different between groups (treatment: 0.86%, n= 7; placebo: 1.35%, n =11; p =0.33). In people without precancerous lesions at baseline, risk of gastric cancer was significantly lower for treatment compared with placebo (incidence of gastric cancer: treatment n =0; placebo n =6; p =0.02) but there was no difference among people with precancerous lesions (n =7 and 5, respectively). Smoking (hazard ratio [HR] 6.2, 95% CI 2.3 to 16.5) and older age (HR per 1 year 1.10, 95% CI 1.05 to 1.15) were independent predictors of gastric cancer risk. Authors' conclusions. Incidence of gastric cancer was similar between H. pylori eradication and placebo groups over 7.5 years of follow-up. However, it was significantly reduced in a subgroup of people without precancerous lesions at baseline.

Original languageEnglish
Pages (from-to)218-220
Number of pages3
JournalEvidence-Based Healthcare
Volume8
Issue number4
DOIs
Publication statusPublished - 2004 Aug

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Fingerprint Dive into the research topics of 'H. pylori eradication does not reduce gastric cancer incidence in a high-risk area of China'. Together they form a unique fingerprint.

Cite this